Efficacy and safety of TAS-102 in refractory metastatic colorectal cancer: a meta-analysis

References

• FerlayJSoerjomataramIDikshitRCancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012Int J Cancer20151365E359E38625220842
   PubMed Web of Science ®Google Scholar
• AritaSShirakawaTMatsushitaYEfficacy and safety of TAS-102 in clinical practice of salvage chemotherapy for metastatic colorectal cancerAnticancer Res20163641959196627069187
   PubMed Web of Science ®Google Scholar
• Van CutsemECervantesANordlingerBArnoldDGroup EGWMetastatic colorectal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-upAnn Oncol201425suppl 3iii1iii925190710
   PubMed Web of Science ®Google Scholar
• KarapetisCSKhambata-FordSJonkerDJK-ras mutations and benefit from cetuximab in advanced colorectal cancerN Engl J Med2008359171757176518946061
   PubMed Web of Science ®Google Scholar
• VenookAPNiedzwieckiDLenzHJCancer and leukemia group B (Alliance), SWOG, and ECOG: CALGB/SWOG 80405: phase III trial of FOLFIRI or mFOLFOX6 with bevacizumab or cetuximab for patients with KRAS wild-type untreated metastatic adenocarcinoma of the colon or rectumJ Clin Oncol2014325s
   PubMedGoogle Scholar
• ChanDLHSegelovEWongRSEpidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer (Review)Cochrane Database Syst Rev20176CD00704728654140
   PubMedGoogle Scholar
• van der VeldenDLOpdamFLOpdamFLTAS-102 and the quest for predictive biomarkersESMO open201724e00026329018579
   PubMed Web of Science ®Google Scholar
• van der VeldenDLOpdamFLVoestEETAS-102 for treatment of advanced colorectal cancers that are no longer responding to other therapiesClin Cancer Res201622122835283927126991
   PubMed Web of Science ®Google Scholar
• SuenagaMSchirripaMCaoSPotential role of polymorphisms in the transporter genes ENT1 and MATE1/OCT2 in predicting TAS-102 efficacy and toxicity in patients with refractory metastatic colorectal cancerEur J Cancer20178619720628992563
   PubMed Web of Science ®Google Scholar
• TemminkOHEmuraTde BruinMFukushimaMPetersGJTherapeutic potential of the dual-targeted TAS-102 formulation in the treatment of gastrointestinal malignanciesCancer Sci200798677978917441963
   PubMed Web of Science ®Google Scholar
• YoshinoTMizunumaNYamazakiKTAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trialLancet Oncol20121310993100122951287
   PubMed Web of Science ®Google Scholar
• MayerRJVan CutsemEFalconeARandomized trial of TAS-102 for refractory metastatic colorectal cancerN Engl J Med2015372201909191925970050
   PubMed Web of Science ®Google Scholar
• MarcusLLemerySJKhasarSFDA approval summary: TAS-102Clin Cancer Res201723122924292728213365
   PubMed Web of Science ®Google Scholar
• HuedomedinaTBSánchezmecaJMarínmartínezFBotellaJAssessing heterogeneity in meta-analysis: Q statistic or I2 index?Psychol Methods200611219316784338
   PubMed Web of Science ®Google Scholar
• XuJKimTWShenLResults of a randomized, double-blind, placebo-controlled, phase III trial of trifluridine/tipiracil (TAS-102) monotherapy in Asian patients with previously treated metastatic colorectal cancer: the TERRA studyJ Clin Oncol201836435035829215955
   PubMed Web of Science ®Google Scholar
• ColucciGGebbiaVPaolettiGGruppo Oncologico Dell’Italia MeridionalePhase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell’Italia MeridionaleJ Clin Oncol200523224866487515939922
   PubMed Web of Science ®Google Scholar
• PetersGJBijnsdorpIVTAS-102: more than an antimetaboliteLancet Oncol20121312e51823182191
   PubMed Web of Science ®Google Scholar
• LenzHJStintzingSLoupakisFTAS-102, a novel antitumor agent: a review of the mechanism of actionCancer Treat Rev201541977778326428513
   PubMed Web of Science ®Google Scholar
• BijnsdorpIVPetersGJTemminkOHFukushimaMKruytFADifferential activation of cell death and autophagy results in an increased cytotoxic potential for trifluorothymidine compared to 5-fluorouracil in colon cancer cellsInt J Cancer2010126102457246819816940
   PubMed Web of Science ®Google Scholar
• MatsuokaKIimoriMNiimiSTrifluridine induces p53-dependent sustained G2 phase arrest with its massive misincorporation into DNA and few DNA strand breaksMol Cancer Ther20151441004101325700705
   PubMed Web of Science ®Google Scholar
• BronckaersAGagoFBalzariniJLiekensSThe dual role of thymidine phosphorylase in cancer development and chemotherapyMed Res Rev200929690395319434693
   PubMed Web of Science ®Google Scholar
• GrotheyAVan CutsemESobreroACORRECT Study GroupRegorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trialLancet2013381986330331223177514
   PubMed Web of Science ®Google Scholar
• LiJQinSXuRCONCUR InvestigatorsRegorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trialLancet Oncol201516661962925981818
   PubMed Web of Science ®Google Scholar
• AbrahaoABKKoYJBerrySChanKKWA comparison of regorafenib and TAS-102 for metastatic colorectal cancer: a systematic review and network meta-analysisClin Colorectal Cancer201717211312029174481
   PubMed Web of Science ®Google Scholar
• MasuishiTTaniguchiHHamauchiSRegorafenib versus trifluridine/tipiracil for refractory metastatic colorectal cancer: a retrospective comparisonClin Colorectal Cancer2017162e15e2227670892
   PubMed Web of Science ®Google Scholar
• SuedaTSakaiDKudoTEfficacy and safety of regorafenib or TAS-102 in patients with metastatic colorectal cancer refractory to standard therapiesAnticancer Res2016368429927466548
   PubMed Web of Science ®Google Scholar
• GrotheyAMarshallJLSeeryTECurrent options for third-line treatment of metastatic colorectal cancerClin Adv Hematol Oncol2016143 suppl 3115
   PubMedGoogle Scholar
• IshidaKSakamotoKTanakaN22 Novel combination therapy, TAS-102 combined with the anti-EGFR antibody or the anti-VEGF antibody showed therapeutic benefit toward colorectal cancer xenograftsEur J Cancer20145061313
   Google Scholar
• TsukiharaHNakagawaFSakamotoKEfficacy of combination chemotherapy using a novel oral chemotherapeutic agent, TAS-102, together with bevacizumab, cetuximab, or panitumumab on human colorectal cancer xenograftsOncol Rep20153352135214225812794
   PubMed Web of Science ®Google Scholar
• KubokiYNishinaTShinozakiETAS-102 plus bevacizumab for patients with metastatic colorectal cancer refractory to standard therapies (C-TASK FORCE): an investigator-initiated, open-label, single-arm, multicentre, phase 1/2 studyLancet Oncol20171891172118128760399
   PubMed Web of Science ®Google Scholar
• TemminkOHHoebeEKBornKVDAcklandSPFukushimaMPetersGJMechanism of trifluorothymidine potentiation of oxaliplatin-induced cytotoxicity to colorectal cancer cellsBr J Cancer200796223117242697
   PubMed Web of Science ®Google Scholar
• BabaYTamuraTSatohYPanitumumab interaction with TAS2 leads to combinational anticancer effects via blocking of EGFR-mediated tumor response to trifluridineMol Oncol20171181065107728486761
   PubMed Web of Science ®Google Scholar
• BurkiTKTAS-102 in metastatic colorectal cancerLancet Oncol2018191e1829249306
   PubMed Web of Science ®Google Scholar